Highlights and Quick Summary
- Ending Cash for the quarter ending June 30, 2023 was $-1.61 Million (a -105.6% decrease compared to previous quarter)
- Year-over-year quarterly Ending Cash decreased by -97.91%
- Annual Ending Cash for 2022 was $26.5 Million (a -91.12% decrease from previous year)
- Annual Ending Cash for 2021 was $299 Million (a 12450.19% increase from previous year)
- Twelve month Ending Cash ending June 30, 2023 was $-66 Million (a -71.57% decrease compared to previous quarter)
- Twelve month trailing Ending Cash increased by 297.91% year-over-year
Trailing Ending Cash for the last four month:
| 30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
|---|---|---|---|
| $-66 Million | $-232 Million | $26.5 Million | $-16.6 Million |
Visit stockrow.com/DSGN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Ending Cash of Design Therapeutics, Inc.
Most recent Ending Cashof DSGN including historical data for past 10 years.Interactive Chart of Ending Cash of Design Therapeutics, Inc.
Design Therapeutics, Inc. Ending Cash for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $-1.61 | $28.81 | – | – | – |
| 2022 | $-16.02 | $-77.14 | $-167.66 | $287.31 | $26.5 |
| 2021 | $-59.09 | $-13.18 | $-29.86 | $400.69 | $298.57 |
| 2020 | $-0.85 | $1.33 | $-0.81 | $2.7 | $2.38 |
Business Profile of Design Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology